MoneyWorks4Me

Gland Pharma gets EIR from USFDA for Pashamylaram facility

18 Jan 2025 Evaluate

Gland Pharma has received Establishment Inspection Report (EIR) from the USFDA for its Pashamylaram facility at Hyderabad. USFDA has conducted inspection for Good Manufacturing Practices (GMP) at said facility between July 25, 2024 and August 02, 2024. The said inspection was concluded with three 483 Observations. 

Gland Pharma develops, manufactures and markets complex injectables. The company sells its products primarily under a business-to-business model in many countries.

Peers
Company Name CMP
Sun Pharma. Inds. 1868.00
Dr. Reddys Labs. 1202.00
Cipla 1385.00
Lupin 2120.00
Zydus Lifesciences 1161.50
View more..